What Is CJC-1295 Without DAC? (Growth Hormone Research)
Research on synthetic growth hormone-releasing hormone (GHRH) analogs has consistently shown one limitation: short half-lives that require frequent dosing and limit practical research applications. CJC-1295 without DAC addresses this by offering a modified GHRH structure that maintains pulsatile growth hormone release patterns while avoiding the prolonged elevation seen with DAC-conjugated versions. The distinction matters because natural growth hormone secretion follows a circadian rhythm. Sustained elevation disrupts feedback loops that pharmaceutical mimetics shouldn't interfere with.
We've synthesized peptides for biological research applications since Real Peptides was founded, and the most common error researchers make isn't storage or reconstitution. It's failing to understand that CJC-1295 without DAC requires coordinated timing with growth hormone secretagogues like ipamorelin to achieve meaningful pulsatile release. The peptide doesn't work in isolation the way marketing materials often suggest.
What is CJC-1295 without DAC?
CJC-1295 without DAC is a 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) that binds to pituitary GHRH receptors and stimulates endogenous growth hormone secretion through pulsatile release patterns. The 'without DAC' designation indicates it lacks the Drug Affinity Complex modification that extends half-life to seven days. Instead, this version has a half-life of approximately 30 minutes, requiring multiple daily administrations. It functions as a research tool for studying growth hormone dynamics, receptor agonism, and the physiological effects of controlled GH elevation.
The term 'without DAC' emerged because the original CJC-1295 formulation included a maleimide-protected cysteine residue that formed covalent bonds with serum albumin. Dramatically extending its duration of action. Researchers recognized that while the DAC version simplified dosing protocols, it also created sustained supraphysiological GH levels that don't mirror natural secretion. CJC-1295 without DAC was developed as a modified GHRH that preserves the pulsatile secretion pattern essential to growth hormone's regulatory feedback mechanisms. This article covers the peptide's mechanism of action, structural modifications that differentiate it from native GHRH, reconstitution and handling protocols for laboratory use, and the specific research contexts where pulsatile GH stimulation provides value over sustained elevation.
Modified GHRH Structure and Receptor Binding Mechanism
CJC-1295 without DAC is structurally distinct from native human GHRH (hGHRH 1-44) through four specific amino acid substitutions that enhance receptor binding affinity and proteolytic resistance. The peptide replaces alanine-2 with D-alanine, preventing enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). The enzyme responsible for rapid GHRH inactivation in plasma. Glutamine-8 is substituted with glutamic acid, leucine-27 with lysine, and arginine-29 is replaced with lysine, creating a sequence that binds GHRH receptors on anterior pituitary somatotrophs with approximately three times the affinity of native GHRH.
The mechanism begins when the peptide binds to GHRH receptors (GHRHR), which are G-protein-coupled receptors expressed primarily on somatotroph cells. Receptor activation stimulates adenylyl cyclase, increasing cyclic AMP (cAMP) production and activating protein kinase A (PKA). This signaling cascade opens voltage-gated calcium channels, triggering calcium influx that causes growth hormone-containing secretory vesicles to fuse with the cell membrane and release GH into circulation. The half-life of CJC-1295 without DAC is approximately 30 minutes following subcutaneous administration. Significantly longer than the 7-minute half-life of native GHRH but far shorter than the 6–8 day half-life of CJC-1295 with DAC.
Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that CJC-1295 without DAC produces peak GH levels 30–60 minutes post-administration, with concentrations returning to baseline within 2–3 hours. This pharmacokinetic profile mirrors the natural pulsatile secretion pattern governed by the hypothalamic GHRH/somatostatin axis, where GH is released in discrete pulses 6–8 times per day, predominantly during slow-wave sleep. The peptide doesn't override somatostatin's inhibitory action. When somatostatin tone is high, GH release remains suppressed even with GHRHR agonism. This explains why CJC-1295 without DAC is typically paired with growth hormone secretagogues (ghrelin mimetics like ipamorelin or GHRP-2) that suppress somatostatin release and amplify the GH pulse.
Reconstitution and Handling Protocols for Laboratory Research
CJC-1295 without DAC is supplied as lyophilized powder in 2mg or 5mg quantities and requires reconstitution with bacteriostatic water before administration in research models. The reconstitution process directly impacts peptide stability. Improper technique introduces aggregation, oxidation, or contamination that renders the compound inactive. Every peptide synthesized by Real Peptides undergoes small-batch production with exact amino-acid sequencing to guarantee purity and consistency, but degradation occurs rapidly once the peptide is in solution if handling protocols aren't followed precisely.
To reconstitute CJC-1295 without DAC, store the lyophilized vial at −20°C until ready for use. Allow the vial to reach room temperature naturally. Never microwave or heat the vial, as temperature spikes denature protein structure. Use bacteriostatic water (0.9% benzyl alcohol) rather than sterile water; the benzyl alcohol prevents bacterial growth in multi-dose vials and extends solution stability. Draw the appropriate volume of bacteriostatic water into a sterile syringe (typically 2mL for a 2mg vial to achieve 1mg/mL concentration) and inject it slowly down the inside wall of the vial. Never inject directly onto the lyophilized powder, as shear force from the stream can break peptide bonds.
Once reconstituted, gently swirl the vial to dissolve the powder. Do not shake. Shaking introduces air bubbles and mechanical stress that cause aggregation. The solution should be clear and colorless; any cloudiness, particulates, or discoloration indicate degradation or contamination. Store reconstituted CJC-1295 without DAC at 2–8°C (standard refrigerator temperature) and use within 28 days. Any temperature excursion above 8°C accelerates degradation. A single exposure to room temperature for 4+ hours can reduce potency by 15–30%, and neither visual inspection nor home testing can detect this loss.
The biggest mistake researchers make when handling peptides isn't contamination. It's injecting air into the vial while drawing solution. The resulting pressure differential pulls contaminants back through the needle on every subsequent draw, even when using sterile technique. Always equalize pressure by withdrawing slightly more air than liquid volume before removing the needle from the vial. For multi-dose protocols, use a separate sterile needle for each draw rather than re-entering the vial with the same needle multiple times.
CJC-1295 Without DAC vs With DAC: Pulsatile vs Sustained GH Elevation
The distinction between CJC-1295 without DAC and CJC-1295 with DAC determines whether the peptide produces physiological pulsatile GH release or sustained supraphysiological elevation. Both peptides share the same core GHRH analog structure, but the DAC modification. A maleimide-protected cysteine residue. Allows the peptide to form covalent bonds with serum albumin, dramatically extending its elimination half-life from 30 minutes to approximately 6–8 days.
Half-Life
~30 minutes
6–8 days
Without DAC requires multiple daily doses; with DAC allows weekly dosing
GH Release Pattern
Pulsatile (peaks 30–60 min, returns to baseline in 2–3 hours)
Sustained elevation (continuous supraphysiological GH for 7+ days)
Without DAC mirrors natural circadian rhythm; with DAC overrides feedback inhibition
Dosing Frequency
2–3x daily (typically paired with GHRP at each administration)
1x weekly (or twice weekly in some protocols)
Without DAC demands strict timing; with DAC offers convenience at the cost of physiological deviation
Somatostatin Sensitivity
Fully responsive. GH release suppressed when somatostatin tone is high
Partially bypasses somatostatin inhibition due to prolonged receptor occupancy
Without DAC respects natural feedback; with DAC can produce GH elevation even during periods when endogenous secretion should be low
Receptor Desensitization Risk
Minimal. Short receptor occupancy allows recovery between pulses
Moderate. Prolonged agonism may downregulate GHRH receptor expression
Without DAC preserves receptor sensitivity; with DAC may require washout periods
Research Application Context
Studies examining pulsatile GH dynamics, circadian secretion patterns, or acute GH effects
Studies requiring sustained GH elevation without frequent dosing (chronic exposure models)
Use without DAC for physiological modeling; with DAC for convenience in long-duration protocols
Growth hormone's biological effects are critically dependent on pulsatile secretion. Continuous GH exposure suppresses downstream IGF-1 production due to negative feedback on hepatic GH receptors, and sustained elevation increases insulin resistance through interference with insulin receptor substrate-1 (IRS-1) signaling. Research published in Endocrinology demonstrated that pulsatile GH administration produced 2.3× greater IGF-1 elevation compared to continuous infusion delivering the same total GH dose over 24 hours. The temporal pattern of receptor engagement matters more than total exposure.
For researchers investigating physiological GH dynamics, metabolic effects, or receptor signaling pathways, CJC-1295 without DAC offers a model that more closely approximates natural hypothalamic-pituitary function. For convenience in chronic administration protocols where strict physiological mimicry isn't the primary endpoint, CJC-1295 with DAC reduces handling complexity. Real Peptides supplies both formulations with identical quality standards. The choice depends entirely on the research question being addressed. You can explore both options through our CJC-1295 NO DAC product or review combination protocols like our CJC1295 Ipamorelin stack.
Key Takeaways
CJC-1295 without DAC is a 29-amino-acid GHRH analog with four amino acid substitutions that enhance receptor binding affinity and resist DPP-IV enzymatic degradation.
The peptide has a 30-minute half-life and produces pulsatile GH release that peaks 30–60 minutes post-administration and returns to baseline within 2–3 hours. Mirroring natural circadian secretion patterns.
CJC-1295 without DAC requires reconstitution with bacteriostatic water and refrigerated storage at 2–8°C; reconstituted solutions remain stable for 28 days if handled correctly.
The 'without DAC' designation indicates the peptide lacks the Drug Affinity Complex modification that extends half-life to 6–8 days. This shorter duration preserves physiological pulsatile GH dynamics.
Pairing CJC-1295 without DAC with growth hormone secretagogues like ipamorelin or GHRP-2 amplifies GH release by suppressing somatostatin inhibition and synergistically activating both GHRH and ghrelin receptor pathways.
Pulsatile GH administration produces significantly greater IGF-1 elevation than continuous infusion with equivalent total GH dose. Temporal receptor engagement patterns determine downstream metabolic effects.
What If: CJC-1295 Without DAC Scenarios
What If the Reconstituted Solution Turns Cloudy After Refrigeration?
Discard the vial immediately. Cloudiness indicates peptide aggregation or bacterial contamination, both of which render the solution unsuitable for research use. Aggregation occurs when peptide chains denature and clump together, forming insoluble particles that cannot bind receptors and may trigger immune responses in animal models. Bacterial contamination introduces endotoxins that confound research results by activating inflammatory pathways independent of the peptide's intended mechanism. Cloudiness can result from temperature excursions (leaving the vial at room temperature for extended periods), contamination during reconstitution (non-sterile technique or reusing needles), or freeze-thaw cycles if the solution was mistakenly frozen after reconstitution. Always reconstitute peptides in a clean workspace using sterile technique, and never attempt to salvage a degraded solution by filtering or diluting it.
What If You Need to Transport CJC-1295 Without DAC to a Different Research Facility?
Transport lyophilized (unreconstituted) peptide in insulated packaging with gel ice packs to maintain temperature between 2–8°C during transit. The peptide tolerates short-term exposure to ambient temperature (up to 25°C for 48 hours) but prolonged heat accelerates degradation. For reconstituted peptide, use a validated cold chain transport container designed for biologics; many commercial coolers cannot maintain the required 2–8°C range for more than 12 hours. Include a temperature data logger to verify that the solution never exceeded 8°C during transport. If a temperature excursion occurred, assume potency loss and adjust research protocols accordingly. Avoid shipping reconstituted peptide unless absolutely necessary; it's safer to ship lyophilized powder and reconstitute at the destination facility.
What If the Peptide Was Accidentally Left at Room Temperature Overnight?
If lyophilized (unreconstituted), the peptide likely retains 85–95% potency. Refrigerate immediately and use within the standard timeframe. If reconstituted, discard the vial. Lyophilized peptides are significantly more stable than reconstituted solutions because the absence of water prevents hydrolysis and limits peptide chain mobility that leads to aggregation. A single overnight exposure (8–12 hours at ~22°C) typically results in 5–15% potency loss for lyophilized powder, which may be acceptable depending on research design. Reconstituted solutions, however, degrade rapidly at room temperature. Bacterial growth accelerates even with bacteriostatic water, and peptide oxidation increases exponentially above 8°C. The visual appearance of the solution won't change, so you cannot rely on inspection to determine viability. Researchers working with temperature-sensitive peptides should consider using our Thymosin Alpha 1 or BPC-157 products, which follow identical handling requirements.
What If Administering CJC-1295 Without DAC Alone Produces Minimal GH Response?
Add a growth hormone secretagogue like ipamorelin or GHRP-2 at the same administration timepoint. CJC-1295 without DAC stimulates GH release through GHRH receptor agonism, but its effectiveness is limited by somatostatin tone. The inhibitory hormone released by the hypothalamus that suppresses GH secretion. Secretagogues act through the ghrelin receptor (growth hormone secretagogue receptor, or GHS-R), which not only triggers GH release independently but also suppresses somatostatin secretion, removing the brake on pituitary somatotrophs. The combined effect is synergistic: studies show that GHRH analogs paired with ghrelin mimetics produce 3–8× greater GH elevation than either compound administered alone. Standard research protocols administer CJC-1295 without DAC at 100–200 mcg per dose alongside ipamorelin at 200–300 mcg per dose, 2–3 times daily, typically before meals and before sleep when endogenous GH pulses naturally occur.
The Mechanistic Truth About CJC-1295 Without DAC
Here's the honest answer: CJC-1295 without DAC doesn't
Frequently Asked Questions
CJC-1295 without DAC stimulates your body’s own pituitary gland to produce and release growth hormone in pulses, whereas exogenous GH injections deliver synthetic hormone directly into circulation. The peptide acts as a GHRH receptor agonist — it amplifies endogenous secretion rather than replacing it. This means CJC-1295 without DAC preserves the natural pulsatile pattern and hypothalamic-pituitary feedback regulation, while direct GH administration overrides endogenous production entirely and can suppress natural GH secretion through negative feedback.
CJC-1295 without DAC can be administered alone, but research consistently shows that pairing it with a growth hormone secretagogue like ipamorelin or GHRP-2 produces 3–8× greater GH elevation than either compound used independently. The GHRH analog stimulates GH release, but somatostatin (the inhibitory hormone) limits this response. Secretagogues act through the ghrelin receptor to suppress somatostatin release, removing the brake and allowing the full GHRH-stimulated pulse to occur. For most research protocols examining robust GH dynamics, combination administration is the standard approach.
Reconstituted CJC-1295 without DAC must be stored at 2–8°C (standard refrigerator temperature) and used within 28 days of reconstitution. Any temperature excursion above 8°C accelerates peptide degradation through oxidation and aggregation — a single exposure to room temperature for 4+ hours can reduce potency by 15–30%. Lyophilized (unreconstituted) powder should be stored at −20°C until ready for use. Never freeze reconstituted peptide solutions, as freeze-thaw cycles cause irreversible protein denaturation.
CJC-1295 without DAC produces peak growth hormone levels 30–60 minutes after subcutaneous administration, with GH concentrations returning to baseline within 2–3 hours. This pharmacokinetic profile mirrors natural pulsatile GH secretion patterns. The peptide’s half-life is approximately 30 minutes, which is significantly longer than native GHRH (7-minute half-life) but far shorter than CJC-1295 with DAC (6–8 day half-life). The short duration requires 2–3 daily administrations to maintain consistent research conditions.
Improper reconstitution introduces aggregation, oxidation, or bacterial contamination that renders the peptide inactive or confounds research results. Common errors include injecting bacteriostatic water directly onto the lyophilized powder (causing shear stress that breaks peptide bonds), shaking rather than gently swirling the vial (introducing mechanical stress and air bubbles), using non-sterile technique (allowing bacterial contamination), and injecting air into the vial while drawing (creating pressure differentials that pull contaminants through the needle). Visual inspection cannot detect many forms of degradation — peptide solutions can appear clear while potency has been reduced by 30% or more.
Both CJC-1295 without DAC and Sermorelin are GHRH analogs that stimulate pituitary GH release, but CJC-1295 without DAC has a significantly longer half-life (30 minutes vs 7 minutes for Sermorelin) due to structural modifications that resist DPP-IV enzymatic degradation. This extended half-life produces more sustained GH elevation per dose and allows slightly less frequent administration. CJC-1295 without DAC also demonstrates approximately 3× higher GHRH receptor binding affinity than Sermorelin. For research protocols requiring longer-duration GH pulses with fewer injections, CJC-1295 without DAC is typically preferred; for models requiring the shortest possible pulse duration most similar to endogenous GHRH, Sermorelin may be more appropriate.
DAC stands for Drug Affinity Complex — a chemical modification (maleimide-protected cysteine residue) that allows the peptide to form covalent bonds with serum albumin, extending its elimination half-life from 30 minutes to 6–8 days. CJC-1295 without DAC lacks this modification, resulting in a much shorter half-life that preserves pulsatile GH secretion patterns rather than producing sustained supraphysiological elevation. The distinction matters because growth hormone’s biological effects depend critically on pulsatile release — continuous GH exposure suppresses IGF-1 production and increases insulin resistance due to receptor desensitization. For research examining physiological GH dynamics, the ‘without DAC’ version is the mechanistically appropriate choice.
Bacteriostatic water (0.9% benzyl alcohol) is strongly recommended for reconstituting CJC-1295 without DAC in multi-dose protocols because the benzyl alcohol prevents bacterial growth in vials that will be accessed multiple times over several weeks. Sterile water can be used for single-dose vials that will be administered immediately after reconstitution, but it offers no antimicrobial protection and significantly shortens the usable lifespan of reconstituted solutions. Most research protocols involve multi-dose vials — for these applications, bacteriostatic water is the standard choice and extends solution stability to 28 days when refrigerated at 2–8°C.
While CJC-1295 without DAC can be administered at any time, research shows that coordinating administration with natural GH secretion patterns produces more consistent and robust responses. Endogenous GH pulses occur predominantly during early morning (6–8 AM), post-exercise, and the first 90 minutes of slow-wave sleep. Administering CJC-1295 without DAC during these windows leverages existing hypothalamic signaling and lower somatostatin tone to amplify the GH pulse. Random-interval dosing produces more variable results because somatostatin inhibition fluctuates throughout the day. Most research protocols administer the peptide 2–3 times daily: morning, post-exercise or mid-afternoon, and before sleep.
Most research protocols reconstitute CJC-1295 without DAC to a concentration of 1mg/mL (1,000 mcg/mL) by adding 2mL of bacteriostatic water to a 2mg vial, or 5mL to a 5mg vial. This concentration allows for convenient dosing — a typical 100–200 mcg dose requires drawing 0.1–0.2mL of solution, which can be measured accurately with standard insulin syringes. Higher concentrations (e.g., 2mg/mL) reduce injection volume but increase the risk of dosing errors; lower concentrations (e.g., 0.5mg/mL) improve precision but require larger injection volumes. The 1mg/mL standard balances accuracy, convenience, and peptide stability.
Lyophilized (unreconstituted) CJC-1295 without DAC should be stored at −20°C for optimal long-term stability, though it tolerates short-term storage at 2–8°C (refrigerator temperature) without significant degradation. The peptide is relatively stable in lyophilized form and can withstand brief exposure to room temperature (up to 25°C for 48 hours) during shipping or handling, though prolonged storage at ambient temperature will gradually reduce potency. Once reconstituted with bacteriostatic water, refrigeration at 2–8°C becomes mandatory — reconstituted solutions degrade rapidly at room temperature and must be kept cold to maintain peptide integrity for the 28-day usable period.
The three most common errors are: (1) administering CJC-1295 without DAC alone without pairing it with a secretagogue, which produces minimal GH elevation due to somatostatin inhibition; (2) improper reconstitution technique — particularly injecting water directly onto the powder or shaking the vial, both of which cause aggregation; and (3) failing to coordinate dosing with natural GH pulse timing, which results in inconsistent responses. A fourth frequent mistake is inadequate temperature control during storage — allowing reconstituted peptide to reach room temperature even briefly accelerates degradation that isn’t visible but significantly reduces potency.